Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Sell
44
LXRX Quote, Financials, Valuation and Earnings
Last price:
$1.32
Seasonality move
:
-9.17%
Day range:
$1.28 - $1.35
52-week range:
$0.28 - $1.83
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.70x
P/B ratio:
3.96x
Volume:
1.1M
Avg. volume:
3.2M
1-year change:
76.72%
Market cap:
$476.1M
Revenue:
$31.1M
EPS (TTM):
-$0.19
Analysts' Opinion
-
Consensus RatingLexicon Pharmaceuticals, Inc. has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $2.92, Lexicon Pharmaceuticals, Inc. has an estimated upside of 122.9% from its current price of $1.31.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $1.31.
Fair Value
-
According to the consensus of 4 analysts, Lexicon Pharmaceuticals, Inc. has 122.9% upside to fair value with a price target of $2.92 per share.
LXRX vs. S&P 500
-
Over the past 5 trading days, Lexicon Pharmaceuticals, Inc. has overperformed the S&P 500 by 8% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Lexicon Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Lexicon Pharmaceuticals, Inc. has grown year-over-year revenues for 10 quarters straight. In the most recent quarter Lexicon Pharmaceuticals, Inc. reported revenues of $14.2M.
Earnings Growth
-
Lexicon Pharmaceuticals, Inc. has grown year-over-year earnings for 6 quarters straight. In the most recent quarter Lexicon Pharmaceuticals, Inc. reported earnings per share of -$0.04.
Enterprise value:
425M
EV / Invested capital:
--
Price / LTM sales:
6.70x
EV / EBIT:
--
EV / Revenue:
6.00x
PEG ratio (5yr expected):
-0.15x
EV / Free cash flow:
-5.75x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$69.8M
Return On Assets:
-25.42%
Net Income Margin (TTM):
-96.77%
Return On Equity:
-49.19%
Return On Invested Capital:
-30.03%
Operating Margin:
-85.93%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $531K | $5.2M | $70.9M | $1.8M | $14.2M | |
| Gross Profit | $6K | $4.3M | $69.8M | $1.6M | $14M | |
| Operating Income | -$155.3M | -$211.1M | -$58M | -$63.7M | -$12.2M | |
| EBITDA | -$154.8M | -$210.6M | -$57.3M | -$63.6M | -$12M | |
| Diluted EPS | -$0.76 | -$0.75 | -$0.19 | -$0.18 | -$0.04 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $124M | $139.1M | $223.4M | $268.6M | $122.5M | |
| Total Assets | $172.3M | $191.7M | $276.5M | $321.1M | $205.9M | |
| Current Liabilities | $34.2M | $18.4M | $32.3M | $36M | $21.7M | |
| Total Liabilities | $35.7M | $47.7M | $137M | $142.6M | $85.8M | |
| Total Equity | $136.6M | $144M | $139.5M | $178.5M | $120.2M | |
| Total Debt | $13.2M | $29.2M | $104.7M | $104.6M | $63.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$132.9M | -$207.8M | -$73.4M | -$53.6M | -$23.8M | |
| Cash From Investing | -$77.7M | -$17.2M | $161.9M | $53.5M | $52.1M | |
| Cash From Financing | $212.9M | $238.5M | -$44.4M | -$916K | -- | |
| Free Cash Flow | -$134.6M | -$208.4M | -$73.9M | -$53.9M | -$23.8M | |
LXRX
Sector
Market Cap
$476.1M
$24M
Price % of 52-Week High
71.59%
48.29%
Dividend Yield
0%
0%
Shareholder Yield
1.68%
-1.62%
1-Year Price Total Return
76.72%
-22.92%
Beta (5-Year)
0.980
0.500
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.27
200-day SMA
Buy
Level
$1.14
Bollinger Bands (100)
Sell
Level
1.23 - 1.49
Chaikin Money Flow
Sell
Level
-8M
20-day SMA
Sell
Level
$1.39
Relative Strength Index (RSI14)
Sell
Level
49.38
ADX Line
Sell
Level
27.88
Williams %R
Neutral
Level
-65.5738
50-day SMA
Buy
Level
$1.30
MACD (12, 26)
Buy
Level
0.34
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Sell
Level
-19.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-9.3101)
Sell
CA Score
(Annual)
Level (-3.7927)
Sell
Beneish M-Score
(Annual)
Level (18.3864)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (4.4096)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
Stock Forecast FAQ
In the current month, LXRX has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The LXRX average analyst price target in the past 3 months is $2.92.
-
Where Will Lexicon Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Lexicon Pharmaceuticals, Inc. share price will rise to $2.92 per share over the next 12 months.
-
What Do Analysts Say About Lexicon Pharmaceuticals, Inc.?
Analysts are divided on their view about Lexicon Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Lexicon Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Lexicon Pharmaceuticals, Inc.'s Price Target?
The price target for Lexicon Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $2.92 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is LXRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Lexicon Pharmaceuticals, Inc. is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of LXRX?
You can purchase shares of Lexicon Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Lexicon Pharmaceuticals, Inc. shares.
-
What Is The Lexicon Pharmaceuticals, Inc. Share Price Today?
Lexicon Pharmaceuticals, Inc. was last trading at $1.32 per share. This represents the most recent stock quote for Lexicon Pharmaceuticals, Inc.. Yesterday, Lexicon Pharmaceuticals, Inc. closed at $1.31 per share.
-
How To Buy Lexicon Pharmaceuticals, Inc. Stock Online?
In order to purchase Lexicon Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get LXRX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
LXRX
Sector
P/E ratio
--
23.44x
PEG ratio
-0.15x
-0.01x
P/B ratio
3.96x
1.73x
Price / LTM sales
6.70x
1.51x
Growth Metrics
LXRX
Sector
Revenue growth
710.4%
3.31%
Earnings growth
80.42%
10.7%
Revenue (5-year growth)
-37.35%
6.28%
Earnings forecast
-$0.07
-$0.19
Profitability
LXRX
Sector
Profitability FY 2024
$29.9M
$2.6M
Return on invested capital
-30.03%
-33.62%
Return on assets
-25.42%
-29.74%
Return on equity
-49.19%
-39.33%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
5
Balance Sheet
LXRX
Sector
Total cash
$116M
$25M
Short term investments
$171.3M
$23.9M
Total assets
$298.4M
$71.9M
Long term debt
$63.3M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Is Sandisk The Next Big Memory Stock?
Computer memory manufacturer Sandisk (NASDAQ:SNDK) has quietly been one of…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
